Archives of Physiology and Biochemistry
The Journal of Metabolic Diseases
ISSN: (Print) (Online) Journal homepage: https://www.tandfonline.com/loi/iarp20
Effects of lacto-ovo-vegetarian diet vs. standard-
weight-loss diet on obese and overweight
adults with non-alcoholic fatty liver disease: a
randomised clinical trial
Nazila Garousi, Babak Tamizifar, Makan Pourmasoumi, Awat Feizi,
Gholamreza Askari, Cain C. T. Clark & Mohammad Hasan Entezari
To cite this article: Nazila Garousi, Babak Tamizifar, Makan Pourmasoumi, Awat Feizi,
Gholamreza Askari, Cain C. T. Clark & Mohammad Hasan Entezari (2021): Effects of lacto-ovo-
vegetarian diet vs. standard-weight-loss diet on obese and overweight adults with non-alcoholic
fatty liver disease: a randomised clinical trial, Archives of Physiology and Biochemistry, DOI:
10.1080/13813455.2021.1890128
To link to this article: https://doi.org/10.1080/13813455.2021.1890128
Published online: 09 Mar 2021.
Submit your article to this journal
Article views: 82
View related articles
View Crossmark data
Full Terms & Conditions of access and use can be found at
https://www.tandfonline.com/action/journalInformation?journalCode=iarp20
ARCHIVESOFPHYSIOLOGYANDBIOCHEMISTRY
https://doi.org/10.1080/13813455.2021.1890128
REVIEW ARTICLE
Effects of lacto-ovo-vegetarian diet vs. standard-weight-loss diet on obese and
overweight adults with non-alcoholic fatty liver disease: a randomised
clinical trial
Nazila Garousia, Babak Tamizifarb, Makan Pourmasoumic , Awat Feizid, Gholamreza Askarie, Cain C. T. Clarkf
and Mohammad Hasan Entezaria
aDepartmentof ClinicalNutrition,FoodSecurity and Nutrition ResearchCenter,School ofNutrition and FoodSciences, Isfahan University of
MedicalSciences, Isfahan,Iran;bGastroenterlogy andHepatology ResearchCenter,Isfahan University ofMedical Sciences, Isfahan,Iran;
cGastrointestinaland LiverDiseases ResearchCenter,Guilan University ofMedicalSciences, Rasht,Iran; dDepartmentof Epidemiologyand
Biostatistics,School ofPublic Health, CardiacRehabilitation Research Center,CardiovascularResearchInstitute, Isfahan University ofMedical
Sciences,Isfahan, Iran;eDepartmentofCommunity Nutrition,FoodSecurity and Nutrition ResearchCenter,School ofNutrition and Food
Sciences,Isfahan University of MedicalSciences, Isfahan,Iran;fCentreforIntelligent Healthcare,CoventryUniversity, Coventry,UK
ABSTRACT ARTICLEHISTORY
The aim of the study was to compare the effects of a lacto-ovo-vegetarian diet (LOV-D) vs. a standard Received5October2020
weight-loss diet (SWL-D) on obese/overweight adults with NAFLD. Present randomised clinical trial Revised13January2021
recruited 75 overweight/obese adults with NAFLD, whowere randomly assigned into LOV-D and SWL- Accepted7February2021
Publishedonline8March
D groups for 3 months. The LOV-D was designed based on eliminating meat, poultry, and fish; while
2021
including dairy products and eggs. The SWL-D was planned according to the standard food pyramid,
whichwasfree in allsources of food.Adherence to LOV-D significantlyoutperformedSWL-D inreduc- KEYWORDS
ing levels of alanine aminotransferase (ALT), body weight, waist circumference, BMI, fasting blood Lacto-ovo-vegetariandiet;
sugar, insulin, homeostasis modelassessment of insulin resistance (HOMA-IR), triacylglycerol (TG), chol- standardweight-lossdiet;
esterol, low-density lipoprotein cholesterol (LDL-C), and systolic blood pressure (SBP). Furthermore, non-alcoholicfattyliver;
ultrasonography revealed a higher alleviation in NAFLD grade among LOV-D, compared with SWL-D. randomisedclinicaltrial
This study suggests that adherence to LOV-D for 3 months has beneficial effects on NAFLD improve-
ment,anthropometricmeasures,glycaemic-relatedmarkers,andlipidprofiles.
Background appropriately, it may progress to chronic liver damage,
including cirrhosis and hepatocellular carcinoma (Angulo
Non-alcoholic fatty liver disease (NAFLD) is the most com-
2002, Loomba and Sanyal 2013). Thus, determining the
mon cause of liver disease worldwide, with NAFLD being
proper treatment is an important issue faced by healthcare
defined as evidence of excessive hepatic fat accumulation in
systems globally. Currently, lifestyle modifications (in the
the absence of remarkable alcohol consumption and second-
form of a healthy diet, physical exercise, and weight loss)
ary causes of hepatic steatosis (Chalasani et al. 2012,
remain the cornerstone of NAFLD management (Liver and
Mansour-Ghanaei et al. 2019). NAFLD affects nearly 14–30%
Diabetes 2016). Implementing a weight-loss diet in the form
of the general population in different parts of the world, and
of caloric restriction, which is standard for omnivorous peo-
it appears that it will dramatically increase over the next two
ple, is the most important intervention for NAFLD treatment,
decades (Bellentani 2017, Mansour-Ghanaei et al. 2018). The
and can reduce visceral, subcutaneous, and hepatic fat, as
exact aetiology of NAFLD is not clearly understood. However, well as promoting weight loss (Clark and Diehl 2003,
several non-modifiable factors, such as age, race, genetic Fontana et al. 2004). Researches have shown that NAFLD
background, and baseline histology, as well as a number of patients who lose 5–7% of their total body weight show
modifiable factors including inappropriate diet, physical improvements in liver enzymes, hepatic fat, insulin sensitivity,
inactivity, weight gain, insulin resistance, and drug abuse and histological changes (Huang et al. 2005, Clark 2006,
have been suggested as the most common contributors in Ratziu 2017).
the onset and progression of NAFLD (Abenavoli et al. 2016, A lacto-ovo-vegetarian diet (LOV-D), which characterised
Hsu et al. 2017). The NAFLD spectrum ranges from simple by variable servings of dairy and eggs as well as vegetables
hepatic steatosis without evidence of hepatocyte injury to and grains, has long been posited to be beneficial for gen-
non-alcoholic steatohepatitis (NASH) with an associated hep- eral health and, in particular, cardiovascular health (Rajaram
atocellular injury. In this regard, if NAFLD is not managed 2003, Rosell 2006). Adherence to this diet is associated with
CONTACTMohammadHasanEntezari entezari@hlth.mui.ac.ir DepartmentofClinicalNutrition,SchoolofNutritionandFoodSciences,IsfahanUniversity
of Medical Sciences, Isfahan, Iran; Makan Pourmasoumi makan.pourmasoumi@gmail.com Gastrointestinal and Liver Diseases Research Center, Guilan
UniversityofMedicalSciences,Rasht,Iran
(cid:1)2021InformaUKLimited,tradingasTaylor&FrancisGroup
2 N.GAROUSIETAL.
improved lipid profiles (Yang et al. 2012) and lower weight regime, and not to consume any supplements and/or medi-
gain (Burke et al. 2008) in comparison with the western diet. cation which might affect the outcomes of interest. All sub-
Additionally, studies have suggested that a vegetarian diet is jects received their dietary plan at the beginning of each
more acceptable among many people, who are more satis- month for 3months. The participants’ adherence to the
fied to follow it for a longer period in compare with other administration of diets was monitored weekly by phone
weight-loss diets (Smith et al. 2000, Burke et al. 2007). As a interview. In addition, subjects were asked to complete a 3-d
vegetarian diet is usually high in calcium, magnesium, anti- dietary record in order to determine compliance with the
oxidant constituents, and fibre, it can improve human insulin study’s dietary goals.
sensitivity, regardless of weight loss or physical activity (Ard
et al. 2004). Although a standard weight-loss diet (SWL-D)
Diet intervention
has long been suggested as a front-line treatment for
NAFLD, there is a lack of evidence regarding the effects of Both diets were caloric-restricted and involved 500kcal less
LOV-D on NAFLD in comparison with SWL-D. Given all the than the energy requirements computed individually for
effectiveness of LOV-D on metabolic markers that involve in each subject. The total energy requirements of each patient
NAFLD development/progression, a hypothesis regarding the were calculated by using the Mifflin-St. Jeor equation,
beneficial clinical application of LOV-D can be laid down. according to resting energy expenditure and the individual’s
Therefore, this study was conducted to compare and deter- physical activity levels (Mifflin et al. 1990). Both diets were
mine the effects of LOV-D and SWL-D on obese and over- planned to consist of approximately 50–55% energy from
weight adults with NAFLD. carbohydrates, 15–20% from protein, and 25–30% from total
fat. The LOV-D was designed based on restraining in the
consumption of meat and meat products, poultry, fish and
Methods
seafood, and flesh of any other animal; but, consisted of diet-
Study participants ary products and eggs as well as all the other food groups.
In this regard, LOV-D nearly included protein sources from
Patients were identified and recruited from February to April egg (24%), dairy (19%), gluten (26%), soy (16%), nuts (8%),
2018. Inclusion criteria required participants to have been vegetables, and fruits (7%). The SWL-D was planned accord-
diagnosed with NAFLD, to be motivated to participate in the ing to the food pyramid, in which all sources of food were
study, aged between 20 and 55years, obese or overweight freely available. Approximately 18% of protein sources in
(BMI > 25kg/m2), and non-consumers of alcohol (<40g/ SWL-D provided from meat and meat products, poultry, fish
week). NAFLD was diagnosed by an ultrasonography scan and seafood, and flesh of any other animal.
and associated with a persistently elevated alanine amino-
transferase (ALT) concentration higher than 19U/L for
Blood sampling and biochemical analyses
women and 30U/L for men (Prati et al. 2002). Participants
were excluded from the study if they were following a spe-
A 10mL blood sample was drawn from participants after a
cial diet, pregnant, breastfeeding, or suffering from viral
12-h overnight fast to determine the concentration of liver
hepatitis, diabetes mellitus, untreated hypothyroidism or enzymes, lipid profiles, and glycaemic status markers. All
other causes of chronic liver disease. The sample size was samples were well-stored in the laboratory at (cid:2)80(cid:3)C before
calculated based on the type one error (a) ¼0.05 and power analysis. Fasting plasma glucose (FBS), fasting insulin, lipid
¼ 0.80%. Considering 20% potential dropout, 80 patients profile including triacylglycerol (TG), total cholesterol (TC),
were estimated as the final sample size. This study was a sin- low-density lipoprotein cholesterol (LDL-C) and high-density
gle-centre, randomised clinical trial. The study protocol was lipoprotein cholesterol (HDL-C), and liver enzymes, such as
approved by the Ethics Committee of Isfahan University of ALT and aspartate aminotransferase (AST) were measured by
Medical Sciences (IR.MUI.REC.1396.3.249) and retrospectively an enzymatic method (Pars Azmoon Co. kit, Tehran, Iran);
registered at the Iranian Registry clinical trial serum insulin concentration was measured by an ELISA kit
(IRCT20140208016529N2). This study was also conducted in (Lise-Meitner-Straße, Kiel, Germany). The homeostasis model
accordance with the CONSORT guidelines. assessment of insulin resistance (HOMA-IR) was calculated by
a previously described formula (Pisprasert et al. 2013).
Study design
Anthropometric measurements and
All participants who were eligible to study were entered into
ultrasonographic assessment
a two-week run-in period. They were requested to provide
their demographic information and a signed written Anthropometric indices, including body weight, height, and
informed consent. After the two-week run-in period, 80 waist circumference were measured by the expert staff at
NAFLD patients were randomly assigned to the LOV-D or the beginning of the study and after the 12-week interven-
SWL-D groups for three months. Randomisation was per- tion. The weight and height of participants were measured
formed using SPSS software version 21 (SPSS Inc, Chicago, IL) while wearing light clothing and no shoes to a precision of
and was stratified according to age, sex, and BMI. Patients 0.1cm (Seca, Hamburg, Germany). Waist circumference was
were instructed to follow their routine physical activity quantified midway between the last rib and the iliac crest.
ARCHIVESOFPHYSIOLOGYANDBIOCHEMISTRY 3
BMI was calculated as weight in kg divided by height in results are expressed as means and standard deviation.
metres squared. Systolic blood pressure (SBP) and diastolic p<.05 is considered as statistically significant.
blood pressure (DBP) were measured 3 times after 5min of
rest using a mercury sphygmomanometer (ALPK2, Zhejiang,
Results
China; Datis Co, Tehran, Iran). The average of the three meas-
urements was then recorded and used in the analyses. Participant characteristics
An ultrasonography blinded assessment was made to
A total of 80 NAFLD patients who met the eligibility criteria
determine the extent of hepatic steatosis at the beginning
were randomly assigned into the LOV-D or SWL-D groups.
and end of the study. Fatty infiltration of the liver was
During the 3 months follow-up, three participants were
graded from 0 to III, which indicated normal liver, mild, mod-
excluded due to having over 10% discontinued intervention
erate, and severe steatosis, respectively, based on several
(n¼2) and emigration (n¼1) from the LOV-D group. Also,
parameters, including the attenuation of echogenicity,
two patients dropped out of the SWL-D group because of
blurred vessels, the liver-to-kidney contrast ratio, and the
over 10% discontinued intervention (n¼1) and travel (n¼1).
brightness of the liver. As this approach is observational,
The attrition rate was not significantly different between the
each assessment was repeated by another radiologist to con-
two groups. Finally, 75 subjects were included in the final
firm the result.
analysis (Figure 1).
Table 1 displays the demographic characteristics of the
Dietary and physical activity assessments two groups at the beginning of the study. Except grade of
NAFLD, there were no significant differences between indi-
In order to evaluate dietary intakes, participants received a 3-
viduals following the LOV-D and SWL-D in terms of
d food record at the beginning, middle, and end of the trial.
anthropometric measurements and demographic
The subjects were instructed to record their daily dietary
information.
intake for three non-consecutive days (two weekdays and
Based on the 3-d dietary records, no significant difference
one weekend day). The data of the food record then was
was found between the two groups at the trial baseline. In
analysed using Nutritionist version 4 software (First
addition, physical activity was not significantly different
Databank, San Bruno, CA), modified for Iranian foods. In
between the two groups pre- and post-intervention (Table
order to enhance the accuracy of the portion size assess-
2). No adverse effect was reported among participants
ment, food scales, and models, as well as national food com-
throughout the study.
position tables, were used as a reference guide for
participants (Ghaffarpour et al. 1999). Physical activity was
also examined by using the metabolic equivalent of task Primary outcomes
(MET) questionnaire (Ainsworth et al. 2000) at the beginning
The liver enzyme concentrations, including ALT and AST,
and end of the trial.
were significantly reduced after the 3-month intervention in
comparison with the baseline values in both groups. The
Primary and secondary outcomes ALT/AST was significantly decreased in the LOV-D group
(p<.001), whereas the reduction of ALT/AST did not reach
The primary outcome was a significant decrease in ALT and significance in the SWL-D group (p¼.078). Adherence to
AST blood levels. The secondary outcome measurements LOV-D resulted in a more significant reduction in ALT
included changes in anthropometric values, insulin metabolic ((cid:2)21.32±19.77 vs. (cid:2)10.15±20.30; p¼.04), but not in and
markers, lipid profiles, blood pressure, and NAFLD grade AST ((cid:2)8.51±11.25 vs. (cid:2)4.15±9.82; p¼.08) and ALT/AST
among participants. (p¼.47), in comparison with SWL-D (Table 3).
Statistical analysis Secondary outcomes
Statistical analyses were performed by using SPSS software Bodyweight, BMI, and waist circumference significantly
version 21 (SPSS Inc, Chicago, IL). The Kolmogorov–Smirnov decreased in both groups. In comparison with SWL-D, a
test was applied to assess the normality of variables distribu- more significant reduction in body weight ((cid:2)5.85±3.09 vs.
tion. Based on the normality of data distribution, a paired- (cid:2)2.20±2.14; p<.001), BMI ((cid:2)2.13±1.04 vs. (cid:2)0.73±0.75;
sample t-test was used to evaluate the change of each vari- p<.001) and waist circumference ((cid:2)7.54±3.64 vs.
able from baseline values. Due to the comparison of changes (cid:2)2.38±1.72; p<.001) were observed in the LOV-D group.
between the LOV-D and SWL-D groups, group comparison Within-group differences demonstrated significant reductions
procedures (including an analysis of variance (ANOVA) test, in TG, TC, LDL-C, FBS, insulin, and HOMA-IR in the LOV-D
repeated measures ANOVA, independent t-test, or the Chi- group. Adherence to the LOV-D diet resulted in significant
square test) were performed, with respect to the type of vari- decreases in TG ((cid:2)48.00±78.20 vs. 10.07±78.54; p¼.006),
ables. An analysis of covariance (ANCOVA) test was applied TC ((cid:2)23.29±29.21 vs. 2.18±44.67; p<.001), LDL-C
to compare the effects of LOV-D and SWL-D on the main ((cid:2)21.24±24.30 vs. 3.36±40.81; p<.001), FBS ((cid:2)8.40±6.20
outcomes while controlling for identified covariates. All vs. (cid:2)1.86±8.50; p¼.001), insulin ((cid:2)4.94±5.40 vs. 0.81±8.35;
Excluded (n=13):
Renal disease (n=2)
Diabetes (n=5)
having a particular diet (n=2)
breast feeding (n=1)
Having medication (n=2)
Hepatitis (n=1)
Lacto-Ovo-Vegetarian Diet
(n=40)
Lost to follow-up (n=3) Lost to follow-up (n=2)
Discontinued intervention more Discontinued intervention more
than 10% (n=2) than 10% (n=1)
Emigration (n=1) Travel (n=1)
Analyzed: (n=37)
Table1. Baselinecharacteristicsofstudyparticipants. D group was 21%. The frequencies of increased NAFLD grade
LOV-D SWL-D were 0.02 and 0% in the SWL-D and LOV-D groups, respect-
Variables number(37) number(38) pValuea ively (Figure 2).
Gradeoffattyliver(%)basedonUS
GradeI 8 18 .02b
GradeII 29 20
Discussion
GradeIII – –
Age(year) 43.51±9.85 42.84±9.85 .769
This study was a randomised clinical trial to determine the
Sex
Woman(%) 22(59.5%) 17(44.7%) .202b effect of LOV-D on obese/overweight adults with NAFLD
Man(%) 15(40.5%) 21(55.3%) independently and in comparison with SWL-D. The results
Smoking 5(13.5%) 6(15.8%) .781
revealed that adherence to LOV-D for 3 months had greater
Physicalactivity(met) 37.14±3.28 37.19±4.10 .680
Weight(kg) 87.16±18.15 85.97±15.46 .234 beneficial effects on anthropometrics measures, ALT, TG, TC,
BMI(kg/m2) 32.02±4.57 30.06±3.81 .105 LDL-C, FBS, insulin metabolic markers, and SBP in comparison
Waist(cm) 109.97±12.29 106.01±10.81 .240
with SWL-D. However, no significant difference was observed
Dataaremeans±SDs.
aObtainedfromindependentt-test. between LOV-D and SWL-D in terms of AST, ALT/AST, HDL,
bObtainedfromChi-squaretest. MAP, and DBP.
LOV-D: lacto-ovo-vegetarian diet; SWL-D: standard-weight-loss diet; BMI: body Diet modification has been widely known as a first-line
massindex;US:ultrasonography
management strategy for NAFLD (Liver and Diabetes 2016).
However, there is a lack of knowledge about the possible
p¼.006), and HOMA-IR ((cid:2)1.62±1.48 vs. 0.02±2.14; p<.001),
beneficial effects of LOV-D on this disease. In accordance
compared with the SWL-D group. Significant decreases in
with this study’s results, the favourable impact of other diets
SBP ((cid:2)0.66±1.06 vs. (cid:2)0.31±0.99; p¼.023) were also found
with high plant-based food content has been previously
in the LOV-D group, compared with the control group.
shown. Mediterranean diet, which is rich in vegetables and
However, there was no difference in HDL (1.56±10.15 vs.
fruits, has been suggested as a way that can improve hepatic
(cid:2)1.23±15.89; p¼.77), DBP ((cid:2)0.29±1.03 vs. (cid:2)0.30±0.89;
insulin sensitivity (Abenavoli et al. 2014), liver enzymes
p¼.31), and MAP ((cid:2)0.41±0.88 vs. (cid:2)0.30±0.76; p¼.13)
(Kontogianni et al. 2014, Razavi Zade et al. 2016), and hepatic
between the two groups (Table 3).
steatosis (Ryan et al. 2013). The Dietary Approach to Stop
Hypertension (DASH – which is characterised by a higher
content of vegetables, fruits, whole grains, low-fat dairy
Liver Doppler sonography
products, fish, poultry, nuts and legumes, while being limited
The findings from the liver ultrasonography revealed a more in sodium, total fat, saturated fat, cholesterol, and added
significant improvement in the LOV-D group, compared to sugars intake (Sacks et al. 2001)) is a different vegetable- and
the SWL-D group (p¼.01). The rate of improvement in LOV- fruit-rich diet which has been the subject of investigations
D subjects was 67%, while the rate of alleviation in the SWL- into NAFLD. In this regard, Razavi Zade et al. (2016) showed
noitacollA
pu-wolloF
sisylanA
Standard-Weight-Loss Diet
(n=40)
Analyzed: (n=38)
tnemllornE
4 N.GAROUSIETAL.
Assessed for eligibility
(n=93)
Randomized (n=80)
Figure1. Participantflowdiagram.
ARCHIVESOFPHYSIOLOGYANDBIOCHEMISTRY 5
Table2. Energy,macronutrientintakes,andphysicalactivityatall-timepoints.
Variables Group Baseline Middleofstudy Endofstudy pValuea
Energy(kcal) LOV-D 2332.07±366.50 2055.50±312.94 1911.02±290.04 .061
SWL-D 2429.17±323.87 2255.27±338.05 2075.54±314.68
pValueb .228 .010 .001
Protein(g) LOV-D 80.40±12.01 79.31±10.57 81.28±10.161 .540
SWL-D 80.83±10.50 78.79±12.17 77.09±11.33
pValueb .868 .845 .96
Carbohydrate(g) LOV-D 354.75±69.88 299.68±63.24 278.44±49.11 .009
SWL-D 376.23±57.36 335.39±55.38 326.54±58.72
pValueb .242 .003 <.001
Fat(g) LOV-D 70.34±10.27 66.31±8.71 60.36±8.62 .408
SWL-D 69.27±10.69 68.11±10.89 64.81±10.67
pValueb .659 .432 .051
Cholesterol(mg) LOV-D 332±119 280±124 298±133 .397
SWL-D 287±136 303±140 264±122
pValueb .131 .459 .252
SFA(g) LOV-D 22.56±3.52 19.32±3.08 18.38±3.11 .004
SWL-D 23.14±4.54 22.49±4.36 21.69±4.46
pValueb .544 .001 <.001
MUFA(g) LOV-D 23.32±3.61 23.09±3.38 20.65±3.33 .991
SWL-D 22.90±4.09 22.57±3.92 21.61±3.90
pValueb .642 .543 .256
PUFA(g) LOV-D 17.70±4.34 17.67±3.04 15.26±2.39 .131
SWL-D 16.33±3.28 16.30±3.37 15.16±3.11
pValueb .128 .069 .877
VitaminC(mg) LOV-D 3466.51±4254 7533.25±9050 9430.13±10548 .004
SWL-D 2630.75±2205 3840.82±5744 3035.47±3453
pValueb .287 .038 .001
Calcium(mg) LOV-D 770.58±190.48 1075.84±155.31 1081.95±170.88 <.001
SWL-D 847.53±177.96 828.32±195.24 792.90±171.34
pValueb .075 <.001 <.001
Magnesium(mg) LOV-D 365.84±73.33 470.61±76.43 482.88±78.67 <.001
SWL-D 370.24±62.16 382.32±58.69 397.40±53.41
pValueb .352 <.001 <.001
Fibretotal(g) LOV-D 27.18±6.05 40.72±7.95 42.32±7.02 <.001
SWL-D 28.21±4.96 29.24±4.99 27.56±6.31
pValueb .421 <.001 <.001
Physicalactivity(met) LOV-D 37.14±3.28 – 38.53±3.95 .721b
SWL-D 37.19±4.10 – 37.14±3.27
pValueb .219 – .101
aObtainedfromrepeatedmeasuredANOVAtest.
bObtainedfromANOVAtest.
that a DASH diet can reduce liver enzyme concentrations, abstaining from meat and meat-related products over time,
body weight, inflammatory factors, some lipid profiles, and as implicated in the study (Burke et al. 2007).
improve insulin sensitivity, in comparison with a con- The main difference between LOV-D and SWL-D is in
trol group. terms of its prohibition of meat. Previous studies have shown
This study revealed that LOV-D has a greater weight that high meat intake is associated with a higher risk of dia-
reduction effect compared with SWL-D. Although the energy betes type 2, through increases in glucose intolerance and
intake in LOV-D was less than SWL-D, and it seems that this impaired insulin sensitivity. Although diabetes and insulin
difference may be the cause of the greater weight reduction resistance are well-known as NAFLD risk factors, the direct
in LOV-D, the trend of change in energy intake during effect of meat on NAFLD has not been investigated. A cross-
3months was not significant between them. In addition, sectional study suggested that meat intake, such as lamb,
after controlling for energy intake and other potential con- beef, liver, sausage, chicken, and turkey was higher in NAFLD
founders, the weight loss effect of diet was more pro- patients, in comparison with healthy adults (Zelber-Sagi et al.
nounced in LOV-D groups. Only sparse data has investigated 2007). However, more studies are needed to investigate the
whether a vegetarian diet differs in terms of weight-loss effi- direct effects of meat and related products on NAFLD and its
cacy. In line with the current results, a study (Valachovi(cid:1)cov(cid:3)a metabolic parameters, especially liver enzymes.
et al. 2006) which matched vegetarians and non-vegetarians The role of higher energy intake on NAFLD risks has been
revealed that non-vegetarians had higher insulin, glucose, well-documented (Wehmeyer et al. 2016). However, the rela-
and homeostasis model assessment measurements than veg- tionship between NAFLD and diet is complicated and is not
etarians. Also, this study showed that vegetarianism has a solely limited to energy intake. Several studies have shown
protective effect on BMI. In contrast with the current results, that NAFLD patients have higher carbohydrate intake, in
Burke et al. (2007) indicated that adherence to LOV-D has no comparison to healthy controls (Cortez-Pinto et al. 2006,
prior effect on anthropometry measurements, compared with Volynets et al. 2012). In addition, results have indicated that
SWL-D in overweight and obese adults. The cause of this protein intake in NAFLD patients is higher than in healthy
inconsistency might be due to declining adherence in participants (Cortez-Pinto et al. 2006, Volynets et al. 2012,
6 N.GAROUSIETAL.
Table3. Metabolicprofiles,anthropometricsmeasures,andbloodpressureatbaselineandafter12-weekinterventioninpatientswithNAFLD.
Variables Before After MD pValuea pValueb
Weight(kg)
LOV-D 87.16±18.15 81.30±17.20 (cid:2)5.85±3.09 <.001 <.001c
SWL-D 85.97±15.46 83.77±15.40 (cid:2)2.20±2.14 <.001
BMI(kg/m2)
LOV-D 32.02±4.57 29.88±4.54 (cid:2)2.13±1.04 <.001 <.001c
SWL-D 30.06±3.8 29.33±3.98 (cid:2)0.73±0.75 <.001
Waistcircumference(cm)
LOV-D 109.97±12.29 102.43±11.68 (cid:2)7.54±3.64 <.001 <.001c
SWL-D 108.39±10.91 106.01±10.81 (cid:2)2.38±1.72 <.001
ALT(IU/L)
LOV-D 46.02±28.58 24.70±15.82 (cid:2)21.32±19.77 <.001 0.04
SWL-D 42.26±23.37 32.10±18.55 (cid:2)10.15±20.30 .004
AST(IU/L)
LOV-D 30.94±13.20 22.43±6.93 (cid:2)8.51±11.25 <.001 .08
SWL-D 29.94±11.14 25.78±9.36 (cid:2)4.15±9.82 .013
ALT/AST
LOV-D 1.470±0.51 1.08±0.46 (cid:2)0.38±0.51 <.001 .47
SWL-D 1.39±0.52 1.21±0.48 (cid:2)0.17±0.60 .078
Triacylglycerol(mg/dL)
LOV-D 169.43±82.95 121.43±49.42 (cid:2)48.00±78.20 .001 .006
SWL-D 171.84±74.45 181.92±81.82 10.07±78.54 .434
Cholesterol(mg/dL)
LOV-D 189.24±26.93 165.94±26.81 (cid:2)23.29±29.21 <.001 <.001
SWL-D 205.97±44.76 208.15±39.38 2.18±44.67 .765
LDL-C
(mg/dL)
LOV-D 114.16±25.75 92.91±24.33 (cid:2)21.24±24.30 <.001 <.001
SWL-D 123.42±38.48 126.78±30.96 3.36±40.81 .614
HDL-C
(mg/dL)
LOV-D 44.75±8.61 46.32±10.37 1.56±10.15 .354 .77
SWL-D 47.91±12.17 46.68±11.96 (cid:2)1.23±15.89 .635
FBS
(mg/dL)
LOV-D 99.05±8.43 90.62±8.77 (cid:2)8.40±6.20 <.001 .001
SWL-D 97.00±10.16 95.13±8.01 (cid:2)1.86±8.50 .184
Insulin
(lU/mL)
LOV-D 22.75±17.70 17.80±17.47 (cid:2)4.94±5.40 <0.001 .006
SWL-D 26.77±24.63 27.59±22.59 0.81±8.35 .550
HOMA-IR
LOV-D 5.59±4.42 3.97±3.75 (cid:2)1.62±1.48 <.001 <.001
SWL-D 6.53±6.46 6.56±5.56 0.02±2.14 .932
SBP
(mmHg)
LOV-D 12.52±1.34 11.86±1.14 (cid:2)0.66±1.06 .001 .023
SWL-D 13.03±1.37 12.72±1.28 (cid:2)0.31±0.99 .058
DBP
(mmHg)
LOV-D 9.82±0.71 9.52±0.75 (cid:2).29±1.03 .090 .31
SWL-D 10.03±0.97 9.73±0.87 (cid:2).30±0.89 .045
MAP
(mmHg)
LOV-D 10.72±0.84 10.30±0.78 (cid:2)0.41±0.88 .007 .13
SWL-D 11.03±1.00 10.73±0.93 (cid:2)0.30±0.76 .018
aObtainedfrompairedt-test.
bObtainedfromANCOVA.Adjustedforbaselinemeasures,BMI,physicalactivity,carbohydrate,anddifferenceinbefore/afterenergyintake.
cAdjustedforbaselinemeasures,carbohydrate,andenergy.
LOV-D:lacto-ovo-vegetariandiet;SWL-D:standard-weight-lossdiet;BMI:bodymassindex;TG:triacylglycerol;TC:total-cholesterol;LDL-C:low-densitylipoprotein;
HDL-C: high-density lipoprotein; FPG: fasting plasma glucose; HOMA-IR: homeostasis model assessment of insulin resistance; SBP: systolic blood pressure; DBP:
diastolicbloodpressure;ALT:alanineaminotransferase;AST:aspartateaminotransferase
Wehmeyer et al. 2016). Diet with higher vegetables and fruits A possible mechanism underlying the efficacy of LOV-D
content provides lower energy density and can act as an on NAFLD might be its high vegetable and fruit content,
essential factor in weight management. However, the role of along with the elimination of meat consumption. Obesity
vegetables and fruits is not limited to their associations with and insulin resistance are the important risk factors for the
lower energy density. They also contain polyphenols and car- onset of NAFLD, which can increase excess fat deposition in
otenoids, which can improve metabolic homeostasis, act as hepatocytes and elevate hepatocyte lipotoxicity and oxida-
anti-inflammatory factors, and suppress hepatic stellate cell tive stress (Yang et al. 2010). Impaired insulin signalling, due
activation (Salomone et al. 2016). to compensatory hyperinsulinemia, also provides more
35 patients’ diet was assessed by 3-d food record and checked
against the participant’s compliance with the advised diet.
30
Furthermore, the subjects in control group consumed more
25 kcal than those in intervention group which may impact on
the results. Due to this reason, the results were adjusted
20
energy intake as well as other confounders to minimise such
15
unfavourable effect and enhance accuracy of conclusion.
10 Lastly, due to the limitations of the study’s resources, ultra-
sonography was used to diagnose and detect NAFLD
5
improvement instead of a fibroscan test. Although ultrason-
0 ography is a validated method for NAFLD detection (Hernaez
LOV-D SWL-D
et al. 2011), there are more precise tests in terms of the
quantification of hepatic fat content (Barchetta et al. 2016).
In this regard, liver enzyme levels, which have been used
clinically as surrogate diagnostic and monitoring markers of
NAFLD (Eliades et al. 2013), were measured to enhance the
overall accuracy of the results. Also, due to the small number
substrate for lipogenesis, elevates hepatic FFAs uptake,
of participants, the results cannot be generalised to large-
decreases b-oxidation, and inhibits glycogen synthesis
scale population groups.
(Mart(cid:3)ın-Dom(cid:3)ınguez et al. 2013, Hardy et al. 2016).
Furthermore, higher calcium and magnesium intake have
favourable effects on improving insulin sensitivity, stimulat-
ing anti-inflammatory response (Almoznino-Sarafian et al. Conclusion
2007, Pikilidou et al. 2009), suppressing the peroxidation of
This study suggested that LOV-D is more effective in treating
lipids cells, and enhancing microsomal triglyceride transfer
NAFLD, compared with SWL-D. Although SWL-D has been
protein hepatic cells (Cho et al. 2005, King et al. 2009).
known as the first-line treatment for NAFLD, the results
Recently, the role of the gut microbiome in many diseases
revealed LOV-D can be a promising therapy, having a greater
has been investigated (Saad et al. 2013). It has been sug-
impact in comparison with SWL-D. In addition, following the
gested that the gut microbiome population is fundamentally
LOV-D resulted in several beneficial impacts on general
different in individuals with obesity, diabetes, metabolic syn-
health, including promoting human health and warding off
drome, and NAFLD (Parnell et al. 2012). The pivotal role of
chronic disease risk factors. Future studies of longer duration
the gut-liver axis in the onset and progress of NAFLD is well-
are warranted to confirm these results.
documented (Eslamparast et al. 2013). Gut-derived lipopoly-
saccharides, which are produced by gram-negative bacteria,
can induce liver injury. It can result in metabolic deregula-
tion, gut permeability, elevated hepatic oxidative stress, and Acknowledgements
fibrosis (Jirillo et al. 2002, Abu-Shanab and Quigley 2010).
The authors thank all the study participants. They are also grateful to
The effect of LOV-D on NAFLD might therefore also be
thestaffofKhorshidHospitalfortheirsupportandcooperation.
related to its fibre content, and how it acts as a prebiotic.
Prebiotics can modify gut microbiota, inhibit pathogen
growth, stimulate the bacterial products of short-chain fatty
Author contributions
acids, and improve lipid and glucose metabolism (Parnell
et al. 2012). Also, the prebiotics can improve liver function
Nazila Garousi, Makan Pourmasoumi, Gholamreza Askari, and
and alleviate levels of ALT and AST (Daubioul et al. 2005). MohammadHasanEntezaricontributedtotheconceptionanddesignof
With regard to the expected difficulties in encouraging the research; NazilaGarousi, Babak Tamizifar, and Awat Fezi contributed
subjects to adhere to specific diets and the high projected to the acquisition and analysis of the data; Nazila Garousi and Makan
rate of attrition during the study, there was excellent reten- Pourmasoumi drafted the initial manuscript. All authors critically revised
the manuscript, agree to be fully accountable for ensuring the integrity
tion after 3months in the trial. In addition, adjustments were
andaccuracyofthework,andreadandapprovedthefinalmanuscript.
made in the results to account for major potential confound-
ers. However, there are several limitations that should be
considered when interpreting the data. First, due to the
Disclosure statement
nature of dietary interventions, blinding was not applicable,
which might have resulted in reporting bias. Second, the
Theauthorsdeclarenoconflictofinterest.
study duration was relatively short. However, even over this
time period, it was possible to show the prominent beneficial
effects of LOV-D on NAFLD treatment. Third, the patients’ Funding
adherence to the diet relied on self-reporting, which might Thisresearchreceived nospecificgrant fromanyfunding agencyinthe
have resulted in misstatements. To manage this bias, the public,commercial,ornot-for-profitsectors.
stnapicitrap
fo
rebmuN
ARCHIVESOFPHYSIOLOGYANDBIOCHEMISTRY 7
Improved
Unchanged
Worse
Ditary intervention groups
Figure 2. Comparison of the changes in liver improvement after a 3-month
intervention with LOV-D and SWL-D. Between-group p values were obtained
from the Chi-square test. LOV-D: lacto-ovo-vegetarian diet; SWL-D: standard-
weight-lossdiet.
8 N.GAROUSIETAL.
ORCID Fontana, L., et al., 2004. Long-term calorie restriction is highly effective
in reducing the risk for atherosclerosis in humans. Proceedings of the
MakanPourmasoumi http://orcid.org/0000-0001-9335-7276 nationalacademyofsciences,101(17),6659–6663.
Ghaffarpour, M., Houshiar-Rad, A., and Kianfar, H., 1999. The manual for
household measures, cooking yields factors and edible portion of foods.
Data availability statement
Tehran:NashreOlumeKeshavarzy.
Hardy, T., et al., 2016. Nonalcoholic fatty liver disease: pathogenesis and
Thedatathatsupportthefindingsofthisstudyareavailableonrequest diseasespectrum.Annualreviewofpathology,11,451–496.
fromthecorrespondingauthor,M-H.E.
Hernaez,R.,etal.,2011.Diagnosticaccuracyandreliabilityofultrasonog-
raphy for the detection of fatty liver: a meta-analysis. Hepatology, 54
(3),1082–1090.
References
Hsu, C.C., Ness, E., and Kowdley, K.V., 2017. Nutritional approaches to
achieve weight loss in nonalcoholic fatty liver disease. Advances in
Abenavoli,L.,etal.,2016.Metabolicaspectsofadultpatientswithnonal-
nutrition,8(2),253–265.
coholic fatty liver disease. World journal of gastroenterology, 22 (31),
7006–7016. Huang, M.A., et al., 2005. One-year intense nutritional counseling results
in histological improvement in patients with non-alcoholic steatohe-
Abenavoli,L.,etal.,2014.Alimentaryregimeninnon-alcoholicfattyliver
patitis:apilotstudy.TheAmericanjournalofgastroenterology,100(5),
disease:Mediterraneandiet.Worldjournalofgastroenterology,20(45),
1072–1081.
16831–16840.
Jirillo,E.,etal.,2002.TheroleoftheliverintheresponsetoLPS:experi-
Abu-Shanab, A. and Quigley, E.M., 2010. The role of the gut microbiota
mental and clinical findings. Journal of endotoxin research, 8 (5),
innonalcoholicfattyliverdisease.Naturereviewsgastroenterologyand
319–327.
hepatology,7(12),691–701.
King, J.L., et al., 2009. Inadequate dietary magnesium intake increases
Ainsworth, B.E., et al., 2000. Compendium of physical activities: an
atherosclerotic plaque development in rabbits. Nutrition research, 29
update of activity codes and MET intensities. Medicine and science in (5),343–349.
sportsandexercise,32(9),S498–S504.
Kontogianni, M.D., et al., 2014. Adherence to the Mediterranean diet is
Almoznino-Sarafian,D.,etal.,2007.MagnesiumandC-reactiveproteinin
associated with the severity of non-alcoholic fatty liver disease.
heart failure: an anti-inflammatory effect of magnesium administra- Clinicalnutrition,33(4),678–683.
tion?Europeanjournalofnutrition,46(4),230–237.
Liver,E.A.F.T.S.O.T.andDiabetes,E.A.F.T.S.O.,2016.EASL-EASD-EASOclin-
Angulo, P., 2002. Nonalcoholic fatty liver disease. The new England jour- ical practice guidelines for the management of non-alcoholic fatty
nalofmedicine,346(16),1221–1231. liverdisease.Obesityfacts,9(2),65–90.
Ard, J.D., et al., 2004. The effect of the PREMIER interventions on insulin Loomba, R. and Sanyal, A.J., 2013. The global NAFLD epidemic. Nature
sensitivity.Diabetescare,27(2),340–347. reviewsgastroenterologyandhepatology,10(11),686–690.
Barchetta, I., et al., 2016. No effects of oral vitamin D supplementation Mansour-Ghanaei, F., et al., 2018. Green tea as a safe alternative
onnon-alcoholicfattyliverdiseaseinpatientswithtype2diabetes:a approach for nonalcoholic fatty liver treatment: a systematic review
randomized, double-blind, placebo-controlled trial. BMC medicine, 14 and meta-analysis of clinical trials. Phytotherapy research, 32 (10),
(1),92. 1876–1884.
Bellentani,S.,2017.Theepidemiologyofnon-alcoholicfattyliverdisease. Mansour-Ghanaei, F., et al., 2019. Efficacy of curcumin/turmeric on liver
Liverinternational,37,81–84. enzymes in patients with non-alcoholic fatty liver disease: a system-
Burke,L.E.,etal.,2007.Effectsofavegetariandietandtreatmentprefer- atic review of randomized controlled trials. Integrative medicine
ence on biochemical and dietary variables in overweight and obese research,8(1),57–61.doi:
adults: a randomized clinical trial. The American journal of clinical Mart(cid:3)ın-Dom(cid:3)ınguez, V., et al., 2013. Pathogenesis, diagnosis and treat-
nutrition,86(3),588–596. mentofnon-alcoholicfattyliverdisease.Revistaespanoladeenferme-
Burke, L., et al., 2008. A randomized clinical trial of a standard versus
dadesdigestivas,105(7),409–420.
vegetarian diet for weight loss: the impact of treatment preference. Mifflin, M.D., et al., 1990. A new predictive equation for resting energy
Internationaljournalofobesity,32(1),166–176. expenditure in healthy individuals. The American journal of clinical
Chalasani, N., et al., 2012. The diagnosis and management of non-alco-
nutrition,51(2),241–247.
Parnell, J.A., et al., 2012. The potential role of prebiotic fibre for treat-
holic fatty liver disease: practice guideline by the American
mentandmanagementofnon-alcoholicfattyliverdiseaseandassoci-
Gastroenterological Association, American Association for the Study
ated obesity and insulin resistance. Liver international, 32 (5),
of Liver Diseases, and American College of Gastroenterology.
701–711.
Gastroenterology,142(7),1592–1609.
Pikilidou,M.,etal.,2009.Insulinsensitivityincreaseaftercalciumsupple-
Cho, H. J., et al., 2005. The possible role of Ca2þ on the activation of
mentationandchangeinintraplateletcalciumandsodium–hydrogen
microsomal triglyceride transfer protein in rat hepatocytes. Biological
exchange in hypertensive patients with Type 2 diabetes 1. Diabetic
andpharmaceuticalbulletin,28(8),1418–1423.
medicine,26(3),211–219.
Clark, J.M., 2006. Weight loss as a treatment for nonalcoholic fatty liver
Pisprasert,V.,etal.,2013.Limitationsintheuseofindicesusingglucose
disease.Journalofclinicalgastroenterology,40,S39–S43.
and insulin levels to predict insulin sensitivity: impact of race and
Clark, J.M. and Diehl, A.M., 2003. Nonalcoholic fatty liver disease: an
genderandsuperiorityoftheindicesderivedfromoralglucosetoler-
underrecognized cause of cryptogenic cirrhosis. JAMA, 289 (22), ancetestinAfricanAmericans.Diabetescare,36(4),845–853.
3000–3004.
Prati, D., et al., 2002. Updated definitions of healthy ranges for serum
Cortez-Pinto,H.,etal.,2006.Howdifferentisthedietarypatterninnon- alanine aminotransferase levels. Annals of internal medicine, 137 (1),
alcoholicsteatohepatitispatients?Clinicalnutrition,25(5),816–823. 1–10.
Daubioul, C., et al., 2005. Effects of oligofructose on glucose and lipid Rajaram, S., 2003. The effect of vegetarian diet, plant foods, and phyto-
metabolism in patients with nonalcoholic steatohepatitis: results of a chemicalsonhemostasisandthrombosis.TheAmericanjournalofclin-
pilotstudy.Europeanjournalofclinicalnutrition,59(5),723–726. icalnutrition,78(3),552S–558S.
Eliades, M., et al., 2013. Meta-analysis: vitamin D and non-alcoholic fatty Ratziu,V.,2017.Non-pharmacologicalinterventionsinnon-alcoholicfatty
liver disease. Alimentary pharmacology and therapeutics, 38 (3), liverdiseasepatients.Liverinternational,37,90–96.
246–254. Razavi Zade, M., et al., 2016. The effects of DASH diet on weight loss
Eslamparast, T., et al., 2013. Probiotics and nonalcoholic fatty liver dis- andmetabolicstatusinadultswithnon-alcoholicfattyliverdisease:a
ease.Middleeastjournalofdigestivediseases,5(3),129–136. randomizedclinicaltrial.Liverinternational,36(4),563–571.
ARCHIVESOFPHYSIOLOGYANDBIOCHEMISTRY 9
Rosell, M., et al., 2006. Weight gain over 5 years in 21 966 meat-eating, Volynets, V., et al., 2012. Nutrition, intestinal permeability, and
fish-eating, vegetarian, and vegan men and women in EPIC-Oxford. blood ethanol levels are altered in patients with nonalcoholic fatty
Internationaljournalofobesity,30(9),1389–1396. liver disease (NAFLD). Digestive diseases and sciences, 57 (7),
Ryan, M.C., et al., 2013. The Mediterranean diet improves hepatic stea- 1932–1941.
tosisandinsulinsensitivityinindividualswithnon-alcoholicfattyliver Wehmeyer, M.H., et al., 2016. Nonalcoholic fatty liver disease is associ-
disease.Journalofhepatology,59(1),138–143. atedwithexcessivecalorieintakeratherthanadistinctivedietarypat-
Saad, N., et al., 2013. An overview of the last advances in probiotic and tern.Medicine,95(23),e3887.
prebioticfield.LWT–foodscienceandtechnology,50(1),1–16. Yang, L., et al., 2010. Defective hepatic autophagy in obesity promotes
Sacks, F.M., et al., 2001. Effects on blood pressure of reduced dietary ER stress and causes insulin resistance. Cell metabolism, 11 (6),
sodium and the Dietary Approaches to Stop Hypertension (DASH) 467–478.
diet.NewEnglandjournalofmedicine,344(1),3–10. Yang, S. Y., et al., 2012. Chinese lacto-vegetarian diet exerts favorable
Salomone, F., Godos, J., and Zelber-Sagi, S., 2016. Natural antioxidants effects on metabolic parameters, intima-media thickness, and cardio-
fornon-alcoholicfattyliverdisease:moleculartargetsandclinicalper- vascular risks in healthy men. Nutrition in clinical practice, 27 (3),
spectives.Liverinternational,36(1),5–20. 392–398.
Smith, C.F., Burke, L.E., and Wing, R.R., 2000. Vegetarian and weight-loss Zelber-Sagi, S., et al., 2007. Long term nutritional intake and the risk for
dietsamongyoungadults.Obesityresearch,8(2),123–129. non-alcoholic fatty liver disease (NAFLD): a population based study.
Valachovi(cid:1)cov(cid:3)a, M., et al., 2006. No evidence of insulin resistance in Journalofhepatology,47(5),711–717.
normal weight vegetarians. European journal of nutrition, 45 (1),
52–54.
